Oncology

Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.

Lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy.

Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.

Lisa Cordes, PharmD, BCACP, BCOP, oncology clinical pharmacy specialist at the National Institutes of Health, discusses treatment options and telehealth for prostate cancer care.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.

The research team used the National Cancer Institute’s Surveillance, Epidemiology, and End Results database, which provides nationwide information on cancer statistics.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

BRACAnalysis CDx assay is indicated for use as a companion diagnostic to select patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who may derive clinical benefit from olaparib.

Dr. Seiko Diane Yamada, MD, the 53rd president of Society of Gynecologic Oncology (SGO), discussed her goals for SGO during her tenure.

Olaparib (Lynparza) approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the growing shift to biosimilars in oncology and the impact of increased access and reduced financial burden for patients on medication adherence.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.

Supplemental new drug application submitted to the FDA for the approval of darolutamide (Nubeqa) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Phase 3 TROPiCS-02 study continues to follow patients for overall survival, a key secondary endpoint.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Pharmacy Times will be covering the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer live in Phoenix, Arizona, taking place March 18 through 21.

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Ivosidenib in combination with azacitidine found to significantly improve event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the adverse events patients with ovarian cancer have reported during treatment with rucaparib.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.